Who is Karen S. Lynch and what is her background?

Karen S. Lynch is a seasoned healthcare executive with over three decades of experience. She most recently served as the President and CEO of CVS Health, a major health solutions company. Her prior roles include executive positions at Aetna, Magellan Health Services, and Cigna Corporation. She also began her career as a Certified Public Accountant at Ernst & Young LLP.

What is the significance of Ms. Lynch's appointment to Thermo Fisher Scientific's Board?

Ms. Lynch's appointment brings a wealth of experience in the healthcare industry and strong executive leadership to the Board. Her background is expected to provide valuable insights, particularly as she is anticipated to serve on the Audit Committee, enhancing the Board's oversight capabilities.

How will Ms. Lynch be compensated for her role as a director?

Ms. Lynch will be compensated according to Thermo Fisher Scientific's standard agreements and arrangements for non-employee directors. This includes receiving the same annual compensation as other non-employee directors, pro-rated to reflect her service term until the 2025 Annual Meeting of Shareholders. She will also enter into the company's standard form of indemnification agreement.

TMO 8-K: Leadership Changes

Summary

Thermo Fisher Scientific Inc. (TMO) announced a strategic addition to its Board of Directors with the election of Karen S. Lynch, effective February 19, 2025. Ms. Lynch brings extensive experience in the healthcare sector, notably her tenure as former president and CEO of CVS Health, where she oversaw a vast employee base and significant consumer reach. Her appointment is expected to strengthen the Board's expertise, particularly as she is anticipated to serve on the Audit Committee.

Key Highlights

1Thermo Fisher Scientific appointed Karen S. Lynch as a new director to its Board, effective February 19, 2025.
2Ms. Lynch has a distinguished career, including over three decades in healthcare and most recently served as President and CEO of CVS Health.
3Her appointment increases the Board size to twelve members, with a term expiring at the Company's 2025 annual meeting.
4Ms. Lynch is expected to be a valuable addition to the Audit Committee.
5Her extensive background in healthcare and executive leadership is a key strategic asset for the company.
6Ms. Lynch will receive standard compensation for non-employee directors, pro-rated for her service period.

THERMO FISHER SCIENTIFIC INC. 8-K Report, Executive Changes (Feb 19, 2025)

Summary

Key Highlights

Frequently Asked Questions